Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor T-cell therapies for brain tumors have shown limited durability, in part because of an antibody attack on the engineered receptor itself, new research shows. Suppressing that response, either with preconditioning drugs or by redesigning the chimeric antigen receptor, helps make the cells and their therapeutic benefit last.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: